Dabbagh Fatemeh, Schroten Horst, Schwerk Christian
Department of Pediatrics, Pediatric Infectious Diseases, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Pharmaceutics. 2022 Aug 18;14(8):1729. doi: 10.3390/pharmaceutics14081729.
The pharmaceutical research sector has been facing the challenge of neurotherapeutics development and its inherited high-risk and high-failure-rate nature for decades. This hurdle is partly attributable to the presence of brain barriers, considered both as obstacles and opportunities for the entry of drug substances. The blood-cerebrospinal fluid (CSF) barrier (BCSFB), an under-studied brain barrier site compared to the blood-brain barrier (BBB), can be considered a potential therapeutic target to improve the delivery of CNS therapeutics and provide brain protection measures. Therefore, leveraging robust and authentic in vitro models of the BCSFB can diminish the time and effort spent on unproductive or redundant development activities by a preliminary assessment of the desired physiochemical behavior of an agent toward this barrier. To this end, the current review summarizes the efforts and progresses made to this research area with a notable focus on the attribution of these models and applied techniques to the pharmaceutical sector and the development of neuropharmacological therapeutics and diagnostics. A survey of available in vitro models, with their advantages and limitations and cell lines in hand will be provided, followed by highlighting the potential applications of such models in the (neuro)therapeutics discovery and development pipelines.
几十年来,制药研究领域一直面临着神经治疗药物开发的挑战及其固有的高风险和高失败率特性。这一障碍部分归因于脑屏障的存在,脑屏障既被视为药物进入的障碍,也被视为机遇。与血脑屏障(BBB)相比,血脑脊液(CSF)屏障(BCSFB)是一个研究较少的脑屏障部位,可被视为改善中枢神经系统治疗药物递送和提供脑保护措施的潜在治疗靶点。因此,利用强大且真实的BCSFB体外模型,通过对药物对该屏障的预期物理化学行为进行初步评估,可以减少在无成效或多余的开发活动上花费的时间和精力。为此,本综述总结了该研究领域所做的努力和取得的进展,特别关注这些模型和应用技术在制药领域以及神经药理学治疗和诊断开发中的作用。将提供对现有体外模型及其优缺点以及现有细胞系的调查,随后重点介绍此类模型在(神经)治疗药物发现和开发流程中的潜在应用。